Fate raises $57M; Biogen vet named CSO at Scholar Rock
San Diego-based Fate Therapeutics $FATE has raised $57 million through a private placement of shares. Redmile bought 2.8 million preferred shares at $13.30 each …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
